Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Lipkowitz

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Research Square|November 19, 2025
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerJung-Min Lee, Junya Tabata, Tzu-Ting Huang, et al.
Frontiers in Pharmacology|April 17, 2023
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancerEmily M J Fennell, Lucas J Aponte-Collazo, Wimal Pathmasiri, et al.
Cancer Research Communications|November 17, 2022
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial HomeostasisYoshimi Endo Greer, Lidia Hernandez, Emily M J Fennell, et al.
Journal for Immunotherapy of Cancer|July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analysesAlexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.
Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.
The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
The Oncologist|June 6, 2023
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaSarah L P Atkins, Yoshimi Endo Greer, Sarah Jenkins, et al.
Nature Communications|March 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyJunya Tabata, Tzu-Ting Huang, Elena Giudice, et al.
Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.
Plos One|February 4, 2010
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinasesYi-Hung Carol Tan, Soundararajan Krishnaswamy, Suvobroto Nandi, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Research Square|November 19, 2025
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerJung-Min Lee, Junya Tabata, Tzu-Ting Huang, et al.
Frontiers in Pharmacology|April 17, 2023
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancerEmily M J Fennell, Lucas J Aponte-Collazo, Wimal Pathmasiri, et al.
Cancer Research Communications|November 17, 2022
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial HomeostasisYoshimi Endo Greer, Lidia Hernandez, Emily M J Fennell, et al.
Journal for Immunotherapy of Cancer|July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analysesAlexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.
Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.
The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
The Oncologist|June 6, 2023
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaSarah L P Atkins, Yoshimi Endo Greer, Sarah Jenkins, et al.
Nature Communications|March 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyJunya Tabata, Tzu-Ting Huang, Elena Giudice, et al.
Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.
Plos One|February 4, 2010
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinasesYi-Hung Carol Tan, Soundararajan Krishnaswamy, Suvobroto Nandi, et al.
Pageof 11